- Investor's Business Daily
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."
- Investor's Business Daily
Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Biohaven stock tumbled Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
- Insider Monkey
argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript May 9, 2024 argenx SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Rob and I will be your conference operator today. I would like to welcome […]
